Ovarian | Maryland Oncology Hematology Ovarian – Maryland Oncology Hematology

Trial ID ESR 22-21698 (EIMPRIS)

clinicaltrials.gov ID
Phase II/III

Trial ID 18194

nct 03748186
clinicaltrials.gov ID
USOR ID: 18194 Phase I
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRá) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Trial ID 20289

clinicaltrials.gov ID
USOR ID: 20289 Phase I
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies

Trial ID 20298

clinicaltrials.gov ID
USOR ID: 20298 Phase II
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer

Trial ID 20156

clinicaltrials.gov ID
USOR ID: 20156 Phase III
A Phase III randomized study to assess the efficacy and safety of alpelisib(BYL719) in combination with olaparib in patients with BRCA wild-type, platinum-resistant or refractory high grade serous ovarian cancer.

Quality Care Close to Home

View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology